Galaxy Biomedical Investment Co., Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 495.707 million compared to CNY 300.799 million a year ago. Operating income was CNY 5.561 million compared to operating loss of CNY 108.903 million a year ago. Net loss was CNY 4.877 million compared to CNY 102.750 million a year ago. Basic loss per share from continuing operations was CNY 0.0044 compared to CNY 0.0934 a year ago.